Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances

Daily Values

Growth Metrics

Others

Unicycive Therapeutics (UNCY) Other financing activities (2022 - 2025)

Unicycive Therapeutics filings provide 2 years of Other financing activities readings, the most recent being $144000.0 for Q2 2023.

On a quarterly basis, Other financing activities fell 51.02% to $144000.0 in Q2 2023 year-over-year; TTM through Sep 2023 was $582000.0, a N/A change, with the full-year FY2024 number at $160000.0, changed N/A from a year prior.
Other financing activities hit $144000.0 in Q2 2023 for Unicycive Therapeutics, roughly flat from $144000.0 in the prior quarter.
In the past five years, Other financing activities ranged from a high of $294000.0 in Q2 2022 to a low of $144000.0 in Q1 2023.